Revised SPC: Taltz (ixekizumab) 80 mg solution for injection in pre-filled syringe

This is now licensed for use in the treatment of moderate to severe plaque psoriasis in children aged ≥6 years and with a body weight of ≥25 kg and adolescents who are candidates for systemic therapy. Information relating to use in this age group has been added.

SPS commentary:

Use in patients with inflammatory bowel disease is now not recommended (previously cautioned). If a patient develops signs and symptoms of inflammatory bowel disease or experiences an exacerbation of pre-existing inflammatory bowel disease, ixekizumab should be discontinued and appropriate medical management should be initiated.


electronic Medicines compendium